NYSE:ANVS
Annovis Bio, Inc.
Annovis Bio, Inc.'s revenue was $0 in fiscal 2025. The diluted share count rose 68.0%.Summary generated from Annovis Bio, Inc.'s SEC filings. Latest annual report filed Mar 13, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−220.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+68.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating income | −15 | −26 | −45 | −27 | −30 |
| Net income | −14 | −25 | −56 | −25 | −29 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- DEF 14AProxy statement
Sep 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of operations and financial condition
Aug 14, 2026 - 8-KOther events
Jul 10, 2026 - 8-KResults of a shareholder vote
Jun 17, 2026 - 4Insider transaction report
May 21, 2026 - 8-KEntry into a material agreement
May 20, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026